The therapeutic value of the periaortic lymphadenectomy in ovarian cancer patients
Affiliation and adress for correspondence

Klinika Nowotworów Narządów Płciowych Kobiecych Centrum Onkologii – Instytut Onkologii im. M. Skłodowskiej-Curie w Warszawie.
Kierownik Kliniki: doc. dr hab. n. med. Mariusz Bidziński
Correspondence to: Klinika Nowotworów Narządów Płciowych Kobiecych, Centrum Onkologii w Warszawie, ul. Roentgena 5, 02-781 Warszawa.
Source of financing: Department own sources

GIN ONKOL, 2005, 3 (2), p. 91-97
ABSTRACT

Introduction: The authors performed an analysis of therapeutic value of lymphadenectomy in patients with ovarian cancer. Material and method: The study encompassed a population of 437 female patients treated at the Centre of Oncology in Warsaw, Poland, since 2000 thru 2002. The influence of lymphadenectomy on disease-free survival and overall survival was analysed. The study population was subdivided into two groups: the first one included 296 patients where lymph nodes were preserved and the second one, including 141 patients, who underwent lymphadenectomy. These groups differed not only as regards lymph node resection, but also in the respect of percentage of optimal procedures. Results: Analysis of this material using proportional risk model revealed, that independent factors related with overall survival were clinical grade, kind of lymphadenectomy and size of residual tumour. The worst prognosis was in the case of patients after pelvic lymphadenectomy only (log-rank p=0.03). Noteworthy is, that patients after both periaortal and pelvic lymphadenectomy, as well as those with their lymph nodes preserved, have similar overall survival rate. Evaluation of disease-free survival revealed, that independent factors were the same as those related to overall survival. Patients after total lymphadenectomy have a 2.6-fold greater chance for longer symptom-free survival. Conclusions: Based on our material we conclude, that lymphadenectomy does not influence overall survival, while extending time to disease progression. These results are concordant with those presented this year after termination of the European randomised clinical trial.

Keywords: ovarian cancer, pelvic lymphadenectomy, aortic lymphadenectomy, overall survival, disease free survival